List of Ravicti drug patents
Ravicti is owned by Horizon Therap.
Ravicti contains Glycerol Phenylbutyrate.
Ravicti has a total of 16 drug patents out of which 0 drug patents have expired.
Ravicti was authorised for market use on 01 February, 2013.
Ravicti is available in liquid;oral dosage forms.
Ravicti can be used as dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder, treatment of a urea cycle disorder.
The generics of Ravicti are possible to be released after 09 March, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183005 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(7 years from now) | |
| US10183006 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(7 years from now) | |
| US10045958 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(7 years from now) | |
| US10183003 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(7 years from now) | |
| US10183002 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(7 years from now) | |
| US10183004 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(7 years from now) | |
| US9962359 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(7 years from now) | |
| US8642012 | HORIZON THERAP | Methods of treatment using ammonia-scavenging drugs |
Sep, 2030
(7 years from now) | |
| US10045959 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(7 years from now) | |
| US9999608 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(7 years from now) | |
| US9561197 | HORIZON THERAP | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Sep, 2030
(7 years from now) | |
| US10668040 | HORIZON THERAP | Treatment of urea cycle disorders in neonates and infants |
Sep, 2030
(7 years from now) | |
| US9254278 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(8 years from now) | |
| US8404215 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging |
Mar, 2032
(8 years from now) | |
| US9326966 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(8 years from now) | |
| US9095559 | HORIZON THERAP | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 28, 2024 |
Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder
Dosage: LIQUID;ORAL
RAVICTI family patents
42
United States
8
Japan
7
European Union
5
Spain
5
China
5
Lithuania
5
Hungary
5
Australia
4
Portugal
4
Croatia
4
Korea, Republic of
4
Cyprus
4
Slovenia
4
Poland
4
Denmark
3
Singapore
3
Mexico
3
Canada
3
Israel
3
Chile
2
United Kingdom
2
Brazil
2
Hong Kong
2
South Africa
2
RS
1
Turkey
1
Norway
1
Ecuador
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic